Declining ALS Patients Are Waiting On The FDA's Next Move
Big Take23 Dec 2022

Declining ALS Patients Are Waiting On The FDA's Next Move

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon and especially insidious form of ALS that runs in families. Patients are urging the US Food and Drug Administration to speed access to the drug, which hasn’t yet been approved because clinical trials didn’t conclusively show it works.

As pharmaceutical companies use new technologies to seek cures of all kinds, this tension between making sure drugs are effective and safe, and offering not-quite-ready but possibly life-saving treatment to people for whom it’s now or never, is becoming more acute.

Bloomberg’s chief medical writer Robert Langreth joins this episode to talk about the race to find a treatment for ALS–and the back and forth between patients, companies and government regulators. We also hear the story of a Pennsylvania family that has passed on a gene for ALS from generation to generation–and their demands for access to the new treatment.

Learn more about the episode here: https://bloom.bg/3WIkvCm

Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK

Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.

See omnystudio.com/listener for privacy information.

Avsnitt(781)

Hims Wants to Keep Mailing You Copycat GLP-1s. It’s Getting Trickier.

Hims Wants to Keep Mailing You Copycat GLP-1s. It’s Getting Trickier.

When a shortage of brand-name weight-loss drugs like Ozempic and Wegovy cleared the way for companies like Hims to fill the gap with cheaper, compounded versions, customers came flocking. But in February, the US Food and Drug Administration announced the shortage was over, leaving the company's strategy in flux and some investors worried. On today’s Big Take podcast, host David Gura and Bloomberg healthcare reporter Madison Muller track how Hims became the king of copycat weight-loss drugs and what’s next for the company as it fights to hold onto the crown. Read more: How Hims Became the King of Knockoff Weight-Loss Drugs Cheap Ozempic Knockoffs Are Suddenly Everywhere. Are They Safe? The Weight-Loss Drug Boom’s Prescription Problem Listen and follow The Big Take on Apple Podcasts, Spotify or wherever you get your podcasts.See omnystudio.com/listener for privacy information.

15 Aug 15min

Why Trump Is Letting Nvidia Sell (Some) AI Chips to China

Why Trump Is Letting Nvidia Sell (Some) AI Chips to China

In an unusual deal, Nvidia and Advanced Micro Devices have agreed to pay the US government 15% of their revenue from AI chips they sell to China. The US has blocked the sale of other, more powerful chips to China on the basis of national security, but the exception underscores the Trump administration’s openness to make exceptions… if the price is right. On today’s Big Take podcast, Bloomberg economic statecraft reporter Joe Deaux joins host Sarah Holder to explain the unprecedented nature of the deal, concerns about its legality and how it fits into Trump’s approach to trade with global competitors.See omnystudio.com/listener for privacy information.

14 Aug 18min

What’s at Stake Ahead of Trump-Putin Meeting

What’s at Stake Ahead of Trump-Putin Meeting

President Donald Trump is heading to Alaska to host a face-to-face meeting with his Russian counterpart, Vladimir Putin to talk about finally, maybe, putting an end to Russia’s war with Ukraine. Notably not invited? Ukraine — or any other European leaders. Today on the show, Bloomberg editor Flavia Krause-Jackson joins host David Gura to talk about why Russia has finally agreed to talk, what’s likely to be on the table in Anchorage and how significant this summit might be.See omnystudio.com/listener for privacy information.

13 Aug 18min

How China Is Bringing Hong Kong’s IPO Market Back to Life

How China Is Bringing Hong Kong’s IPO Market Back to Life

After a years-long slump, Hong Kong’s IPO market is roaring back to life, thanks to a growing number of Chinese companies that are raising billions of dollars in the city. On today’s Big Take Asia Podcast, host K. Oanh Ha and Bloomberg’s Dave Sebastian explore how China is transforming the financial hub into a key funding engine for mainland firms— and the risks this poses for banks on Wall Street and beyond.See omnystudio.com/listener for privacy information.

12 Aug 14min

Who’s Really Paying for Tariffs? Hint: It’s Not Foreign Companies

Who’s Really Paying for Tariffs? Hint: It’s Not Foreign Companies

President Trump’s so-called reciprocal tariffs have pushed the average US tariff rate to 15%, up from just over 2% last year. But who’s actually footing the bill so far? On today’s Big Take podcast, Bloomberg Businessweek’s “Everybody’s Business” host Stacey Vanek Smith takes Sarah Holder through Tariff 101: How is that money being collected and where is it going? Read more: It’s Only a Matter of Time Until Americans Pay for Trump’s TariffsSee omnystudio.com/listener for privacy information.

11 Aug 16min

Who Will Win the Race for Greenland’s Rare Earths?

Who Will Win the Race for Greenland’s Rare Earths?

For years, President Donald Trump has voiced his ambitions to expand the US presence in Greenland. But making that happen is easier said than done. Bloomberg’s Joe Deaux traveled to the remote island this spring, alongside a former Trump administration official who’s hoping to build a rare-earths mine there — with the federal government’s investment. On today’s Big Take podcast, Joe walks host David Gura through what he saw on the ground, what Greenlanders have to say about Trump’s rhetoric and what it would really take to establish a mines-to-magnets pipeline in Greenland. Read more: Greenland’s Rare-Earth Dreams Are Luring Trump AlliesSee omnystudio.com/listener for privacy information.

8 Aug 18min

Private Equity Is Coming for Your 401(k)

Private Equity Is Coming for Your 401(k)

US President Donald Trump just signed an executive order that aims to allow private equity into a $12 trillion piece of America’s retirement market — 401(k)s. On today’s Big Take podcast, private equity reporter Allison McNeely joins host Sarah Holder to explain what this could mean for the average American’s retirement savings. Read more: Trump Signs Order Easing Path for Private Assets in 401(k)sSee omnystudio.com/listener for privacy information.

7 Aug 15min

Inside the Trump Family’s Money-Making Machine

Inside the Trump Family’s Money-Making Machine

Since President Trump kicked off his reelection campaign in November 2022, his net worth has more than doubled — to roughly $6.4 billion. No modern American president has positioned his family to make so much money while in the White House. Today on the show, Bloomberg reporters Max Abelson and Annie Massa join host David Gura to discuss the sources of the Trump family’s wealth — from cryptocurrencies and sneakers to Trump-branded towers in the Middle East. Read more: The Trump Family’s Money-Making MachineSee omnystudio.com/listener for privacy information.

6 Aug 18min

Populärt inom Politik & nyheter

svenska-fall
aftonbladet-krim
motiv
p3-krim
flashback-forever
fordomspodden
rss-viva-fotboll
aftonbladet-daily
rss-krimstad
rss-sanning-konsekvens
rss-vad-fan-hande
olyckan-inifran
spar
blenda-2
politiken
dagens-eko
rss-frandfors-horna
rss-krimreportrarna
rss-expressen-dok
krimmagasinet